Peter Kolchinsky portfolio, Q1 2025
RA Capital Management · 13F for the quarter ending Mar 31, 2025
For Q1 2025, RA Capital Management reported $6B across 85 US-listed positions, led by ASND (26.8%), PCVX (7.7%) and RYTM (5.4%). Compared with its filing for Q4 2024, Peter Kolchinsky opened 11 new positions, added to 14, reduced 4 and sold out of 15; 56 positions did not change.
The largest purchase was an addition to PCVX ($132.2M); the largest sale, the sale of the whole position in LEGN ($244.3M).
Key facts
- 13F portfolio value
- $6BQ1 2025
- Positions
- 85
- Largest holding
- ASND 26.8%
- New positions
- 11
- Sold out
- 15
- Filed
- May 15, 2025
Holdings as of (Q1 2025), filed with the SEC on . Changes are measured against the filing for Dec 31, 2024. Every tracked investor's Q1 2025 13F.
Bought and sold in Q1 2025
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Legend Biotech CorpLEGN | ▼ Sold out | −7.51M | $244.3M | 4.08% |
| Vaxcyte IncPCVX | ▲ Added 40% | +3.5M | $132.2M | 2.21% |
| SPDR Series TrustXBI | ▼ Sold out | −1.23M | $110.6M | 1.85% |
| Sionna Therapeutics IncSION | ▲ New | +10.45M | $109.3M | 1.82% |
| Axsome Therapeutics IncAXSM | ▼ Sold out | −1M | $84.6M | 1.41% |
Verona Pharma Plcno ticker on file | ▼ Sold out | −1.77M | $82.1M | 1.37% |
| Disc Medicine IncIRON | ▲ New | +1.58M | $78.3M | 1.31% |
| Praxis Precision MedicinesPRAX | ▼ Sold out | −761.96K | $58.6M | 0.98% |
| Recursion Pharmaceuticals IncRXRX | ▼ Sold out | −7.73M | $52.2M | 0.87% |
| Geron CorpGERN | ▲ Added 101% | +30.37M | $48.3M | 0.81% |
89BIO Incno ticker on file | ▲ Added 40% | +5.71M | $41.5M | 0.69% |
| Evolent Health IncEVH | ▼ Sold out | −3.58M | $40.2M | 0.67% |
| Scholar Rock Holding CorpSRRK | ▲ Added more than 10× | +1.12M | $36M | 0.60% |
| UroGen Pharma LtdURGN | ▲ New | +3.21M | $35.5M | 0.59% |
| Dyne Therapeutics IncDYN | ▲ Added 52% | +3.33M | $34.9M | 0.58% |
Chimerix Incno ticker on file | ▼ Sold out | −8.8M | $30.6M | 0.51% |
| Newamsterdam Pharma CompanyNAMS | ▲ Added 15% | +1.29M | $26.5M | 0.44% |
| Ascendis Pharma A/SASND | ▲ Added 1.7% | +168.75K | $26.3M | 0.44% |
| Janux Therapeutics IncJANX | ▲ Added 8.0% | +824.04K | $22.2M | 0.37% |
| Mineralys Therapeutics IncMLYS | ▲ Added 27% | +1.3M | $20.6M | 0.34% |
| Glaukos CorpGKOS | ▲ New | +190.26K | $18.7M | 0.31% |
Metsera Incno ticker on file | ▲ New | +675.53K | $18.4M | 0.31% |
| Dianthus Therapeutics IncDNTH | ▲ Added 54% | +1M | $18.1M | 0.30% |
| C4 Therapeutics IncCCCC | ▼ Sold out | −4.88M | $17.6M | 0.29% |
| Pliant Therapeutics IncPLRX | ▼ Sold out | −1.28M | $16.9M | 0.28% |
Arcellx Incno ticker on file | ▲ Added 8.9% | +249.2K | $16.3M | 0.27% |
| 10X Genomics IncTXG | ▼ Reduced 41% | −1.34M | $11.7M | 0.19% |
Third Harmonic Bio Incno ticker on file | ▼ Sold out | −960.62K | $9.9M | 0.17% |
Iteos Therapeutics Incno ticker on file | ▲ Added 74% | +1.56M | $9.3M | 0.16% |
| Bright Minds Biosciences IncDRUG | ▼ Reduced 55% | −254.4K | $9.2M | 0.15% |
| Arcus Biosciences IncRCUS | ▲ New | +1.14M | $8.9M | 0.15% |
| Arvinas IncARVN | ▼ Sold out | −421.35K | $8.1M | 0.13% |
| Acadia Healthcare CompanyACHC | ▲ New | +217K | $6.6M | 0.11% |
| Beta Bionics IncBBNX | ▲ New | +500K | $6.1M | 0.10% |
| Enanta Pharmaceuticals IncENTA | ▼ Sold out | −1.04M | $6M | 0.10% |
| Humacyte IncHUMA | ▲ New | +3.31M | $5.6M | 0.09% |
| Surrozen IncSRZN | ▲ Added 140% | +396.55K | $4.6M | 0.08% |
| Kura Oncology IncKURA | ▼ Reduced 10% | −446.43K | $2.9M | 0.05% |
| Sutro BiopharmaSTRO | ▲ New | +4.43M | $2.9M | 0.05% |
| GH Research PLCGHRS | ▲ Added 3.9% | +257.96K | $2.8M | 0.05% |
Allakos Incno ticker on file | ▼ Sold out | −1.13M | $1.4M | 0.02% |
| Bioage Labs IncBIOA | ▼ Reduced 20% | −258.1K | $970.4K | 0.02% |
| CytomX Therapeutics IncCTMX | ▲ New | +1M | $635.8K | 0.01% |
Regulus Therapeutics Incno ticker on file | ▼ Sold out | −336.84K | $532.2K | 0.01% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND · SPONSORED ADR | Health Care | 26.8% | $1.6B | 10.28M | $155.86 | 4+ qtrs | ▲ Added 1.7% |
| 2 | Vaxcyte IncPCVX | Health Care | 7.69% | $460.3M | 12.19M | $37.76 | 4+ qtrs | ▲ Added 40% |
| 3 | Rhythm Pharmaceuticals IncRYTM | Health Care | 5.38% | $322.3M | 6.08M | $52.97 | 4+ qtrs | No change |
| 4 | Janux Therapeutics IncJANX | — | 5.05% | $302.1M | 11.19M | $27.00 | 4+ qtrs | ▲ Added 8.0% |
| 5 | Newamsterdam Pharma CompanyNAMS | — | 3.47% | $207.5M | 10.14M | $20.47 | 4+ qtrs | ▲ Added 15% |
| 6 | Arcellx Incno ticker on file · SH | — | 3.33% | $199.2M | 3.04M | $65.60 | 4+ qtrs | ▲ Added 8.9% |
| 7 | Edgewise Therapeutics IncEWTX | Health Care | 3.27% | $196M | 8.91M | $22.00 | 4+ qtrs | No change |
| 8 | Avidity Biosciences Incno ticker on file · SH | — | 3.11% | $186M | 6.3M | $29.52 | 4+ qtrs | No change |
| 9 | Wave Life Sciences LtdWVE | — | 2.46% | $147.1M | 18.2M | $8.08 | 4+ qtrs | No change |
| 10 | 89BIO Incno ticker on file · SH | — | 2.42% | $144.6M | 19.89M | $7.27 | 4+ qtrs | ▲ Added 40% |
| 11 | Ars Pharmaceuticals IncSPRY | — | 2.28% | $136.6M | 10.86M | $12.58 | 4+ qtrs | No change |
| 12 | Sionna Therapeutics IncSION | — | 1.83% | $109.3M | 10.45M | $10.46 | 1 qtr | New |
| 13 | Lenz Therapeutics IncLENZ | — | 1.79% | $107.4M | 4.18M | $25.71 | 4+ qtrs | No change |
| 14 | Dyne Therapeutics IncDYN · SH | — | 1.70% | $101.6M | 9.71M | $10.46 | 4+ qtrs | ▲ Added 52% |
| 15 | Tyra Biosciences IncTYRA | — | 1.65% | $98.9M | 10.64M | $9.30 | 4+ qtrs | No change |
| 16 | Mineralys Therapeutics IncMLYS | — | 1.63% | $97.6M | 6.15M | $15.88 | 4+ qtrs | ▲ Added 27% |
| 17 | Geron CorpGERN | — | 1.60% | $96M | 60.38M | $1.59 | 4+ qtrs | ▲ Added 101% |
| 18 | RxSight IncRXST · SH | — | 1.58% | $94.5M | 3.74M | $25.25 | 4+ qtrs | No change |
| 19 | Bicara Therapeutics IncBCAX | — | 1.51% | $90.6M | 6.96M | $13.03 | 3 qtrs | No change |
| 20 | Disc Medicine IncIRON | — | 1.31% | $78.3M | 1.58M | $49.64 | 1 qtr | New |
| 21 | GH Research PLCGHRS | — | 1.28% | $76.6M | 6.94M | $11.03 | 4+ qtrs | ▲ Added 3.9% |
| 22 | Apogee Therapeutics Incno ticker on file · SH | — | 0.98% | $58.6M | 1.57M | $37.36 | 4+ qtrs | No change |
| 23 | Dianthus Therapeutics IncDNTH | Health Care | 0.87% | $52M | 2.87M | $18.14 | 4+ qtrs | ▲ Added 54% |
| 24 | Zai Lab LtdZLAB · ADR | — | 0.78% | $46.8M | 1.3M | $36.14 | 2 qtrs | No change |
| 25 | Day One Biopharmaceuticalsno ticker on file · SH | — | 0.76% | $45.6M | 5.76M | $7.93 | 4+ qtrs | No change |
| 26 | Septerna IncSEPN | — | 0.68% | $40.5M | 7M | $5.79 | 2 qtrs | No change |
| 27 | Tourmaline Bio Incno ticker on file · SH | — | 0.65% | $38.6M | 2.54M | $15.21 | 4+ qtrs | No change |
| 28 | Climb Bio IncCLYM | — | 0.64% | $38.3M | 31.42M | $1.22 | 4+ qtrs | No change |
| 29 | Scholar Rock Holding CorpSRRK · SH | Health Care | 0.61% | $36.5M | 1.14M | $32.15 | 2 qtrs | ▲ Added more than 10× |
| 30 | UroGen Pharma LtdURGN · SH | — | 0.59% | $35.5M | 3.21M | $11.06 | 1 qtr | New |
| 31 | Artiva Biotherapeutics IncARTV | — | 0.49% | $29.6M | 9.85M | $3.00 | 3 qtrs | No change |
| 32 | Fulcrum Therapeutics IncFULC | — | 0.49% | $29.5M | 10.23M | $2.88 | 4+ qtrs | No change |
| 33 | Vor Biopharma IncVOR · SH | — | 0.48% | $28.4M | 39.65M | $0.7175 | 4+ qtrs | No change |
| 34 | Astria Therapeutics Incno ticker on file · SH | — | 0.46% | $27.3M | 5.11M | $5.34 | 4+ qtrs | No change |
| 35 | Kura Oncology IncKURA · SH | — | 0.44% | $26.4M | 4M | $6.60 | 2 qtrs | ▼ Reduced 10% |
| 36 | Structure Therapeutics IncGPCR · SH | — | 0.44% | $26.3M | 1.52M | $17.31 | 4+ qtrs | No change |
| 37 | Cidara Therapeutics Incno ticker on file · SH | — | 0.39% | $23.5M | 1.09M | $21.54 | 3 qtrs | No change |
| 38 | Aerovate Therapeutics Incno ticker on file · SH | — | 0.39% | $23.1M | 9.19M | $2.51 | 4+ qtrs | No change |
| 39 | IDEAYA Biosciences IncIDYA · SH | — | 0.37% | $22.1M | 1.35M | $16.38 | 3 qtrs | No change |
| 40 | Iteos Therapeutics Incno ticker on file · SH | — | 0.36% | $21.8M | 3.65M | $5.97 | 4+ qtrs | ▲ Added 74% |
| 41 | Travere Therapeutics IncTVTX | Health Care | 0.34% | $20.6M | 1.15M | $17.92 | 2 qtrs | No change |
| 42 | Nkarta IncNKTX | — | 0.33% | $19.9M | 10.81M | $1.84 | 4+ qtrs | No change |
| 43 | Glaukos CorpGKOS · SH | Health Care | 0.31% | $18.7M | 190.26K | $98.42 | 1 qtr | New |
| 44 | Monopar Therapeutics IncMNPR | — | 0.31% | $18.6M | 511.21K | $36.41 | 2 qtrs | No change |
| 45 | Metsera Incno ticker on file · SH | — | 0.31% | $18.4M | 675.53K | $27.22 | 1 qtr | New |
| 46 | Eyepoint Pharmaceuticals IncEYPT · SH | — | 0.29% | $17.2M | 3.18M | $5.42 | 2 qtrs | No change |
| 47 | 10X Genomics IncTXG · SH | Health Care | 0.28% | $17M | 1.94M | $8.73 | 2 qtrs | ▼ Reduced 41% |
| 48 | Acrivon Therapeutics IncACRV | — | 0.28% | $16.9M | 8.34M | $2.03 | 4+ qtrs | No change |
| 49 | Enliven Therapeutics IncELVN · SH | — | 0.28% | $16.7M | 848.99K | $19.68 | 4+ qtrs | No change |
| 50 | Acumen Pharmaceuticals IncABOS | — | 0.27% | $16.4M | 14.93M | $1.10 | 4+ qtrs | No change |
| 51 | Solid Biosciences IncSLDB | — | 0.27% | $16M | 4.33M | $3.70 | 4+ qtrs | No change |
| 52 | Ceribell IncCBLL · SH | — | 0.27% | $15.8M | 824.58K | $19.21 | 2 qtrs | No change |
| 53 | Nurix Therapeutics IncNRIX · SH | — | 0.27% | $15.8M | 1.33M | $11.88 | 2 qtrs | No change |
| 54 | Insmed IncINSM · SH | Health Care | 0.26% | $15.3M | 200K | $76.29 | 4+ qtrs | No change |
| 55 | Taysha Gene Therapies IncTSHA | — | 0.25% | $15.1M | 10.87M | $1.39 | 4+ qtrs | No change |
| 56 | Pepgen IncPEPG | — | 0.25% | $15M | 10.69M | $1.41 | 4+ qtrs | No change |
| 57 | 4D Molecular TherapeuticsFDMT | — | 0.25% | $14.7M | 4.56M | $3.23 | 4+ qtrs | No change |
| 58 | Protara Therapeutics IncTARA · SH | — | 0.24% | $14.5M | 3.4M | $4.26 | 4+ qtrs | No change |
| 59 | Larimar Therapeutics IncLRMR · SH | — | 0.22% | $13M | 6.05M | $2.15 | 4+ qtrs | No change |
| 60 | Eledon Pharmaceuticals IncELDN · SH | — | 0.20% | $12.1M | 3.57M | $3.39 | 2 qtrs | No change |
| 61 | Alector IncALEC · SH | — | 0.20% | $11.9M | 9.7M | $1.23 | 2 qtrs | No change |
| 62 | Sera Prognostics IncSERA · SH | — | 0.19% | $11.2M | 3.03M | $3.68 | 4+ qtrs | No change |
| 63 | MBX Biosciences IncMBX · SH | — | 0.19% | $11.2M | 1.51M | $7.38 | 3 qtrs | No change |
| 64 | Bicycle Therapeutics PlcBCYC · SH | — | 0.16% | $9.3M | 1.09M | $8.49 | 4+ qtrs | No change |
| 65 | Arcus Biosciences IncRCUS · SH | — | 0.15% | $8.9M | 1.14M | $7.85 | 1 qtr | New |
| 66 | Surrozen IncSRZN · SH | — | 0.13% | $7.9M | 679.13K | $11.66 | 4+ qtrs | ▲ Added 140% |
| 67 | Immatics N.V.IMTX · SH | — | 0.13% | $7.9M | 1.75M | $4.51 | 4+ qtrs | No change |
| 68 | Avalo Therapeutics IncAVTX | — | 0.13% | $7.7M | 967K | $8.01 | 3 qtrs | No change |
| 69 | Perceptive Cap Solutionsno ticker on file | — | 0.13% | $7.7M | 750K | $10.30 | 4+ qtrs | No change |
| 70 | Bright Minds Biosciences IncDRUG | — | 0.12% | $7.4M | 206.43K | $36.07 | 2 qtrs | ▼ Reduced 55% |
| 71 | Aclaris Therapeutics IncACRS | — | 0.12% | $7.1M | 4.67M | $1.53 | 2 qtrs | No change |
| 72 | Acadia Healthcare CompanyACHC · SH | — | 0.11% | $6.6M | 217K | $30.32 | 1 qtr | New |
| 73 | Beta Bionics IncBBNX · SH | — | 0.10% | $6.1M | 500K | $12.24 | 1 qtr | New |
| 74 | Xencor IncXNCR | — | 0.10% | $6.1M | 575K | $10.64 | 3 qtrs | No change |
| 75 | Werewolf Therapeutics IncHOWL | — | 0.10% | $6M | 6.14M | $0.9722 | 4+ qtrs | No change |
| 76 | Adicet Bio IncACET · SH | — | 0.10% | $5.7M | 7.54M | $0.7550 | 4+ qtrs | No change |
| 77 | Humacyte IncHUMA · SH | — | 0.09% | $5.6M | 3.31M | $1.71 | 1 qtr | New |
| 78 | Zura Bio LtdZURA · SH | — | 0.07% | $4.2M | 3.22M | $1.29 | 4+ qtrs | No change |
| 79 | Bioage Labs IncBIOA | — | 0.07% | $4M | 1.05M | $3.76 | 3 qtrs | ▼ Reduced 20% |
| 80 | Boundless Bio IncBOLD · SH | — | 0.06% | $3.3M | 2.18M | $1.51 | 4+ qtrs | No change |
| 81 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.05% | $3M | 333.33K | $8.99 | 4+ qtrs | No change |
| 82 | Sutro BiopharmaSTRO · SH | — | 0.05% | $2.9M | 4.43M | $0.6506 | 1 qtr | New |
| 83 | Lexeo Therapeutics IncLXEO | — | 0.03% | $1.9M | 546.55K | $3.47 | 4+ qtrs | No change |
| 84 | CytomX Therapeutics IncCTMX · SH | — | 0.01% | $635.8K | 1M | $0.6358 | 1 qtr | New |
| 85 | Scilex Holding Cono ticker on file · SH | — | 0.00% | $257.5K | 1.04M | $0.2485 | 4+ qtrs | No change |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 45.8% | $2.7B | 10 |
| No sector on file | 54.2% | $3.2B | 75 |
Questions and answers
What did Peter Kolchinsky own in Q1 2025?
RA Capital Management's 13F for Q1 2025 lists 85 positions worth $6B. The largest: ASND (26.8%), PCVX (7.7%), RYTM (5.4%), JANX (5.0%), NAMS (3.5%).
What did Peter Kolchinsky buy in Q1 2025?
The largest purchases, by the shares bought at the quarter-end price the filing implies: PCVX (added, $132.2M), SION (new, $109.3M), IRON (new, $78.3M), GERN (added, $48.3M), 89BIO Inc (added, $41.5M), SRRK (added, $36M).
What did Peter Kolchinsky sell in Q1 2025?
The largest sales: LEGN (sold out, $244.3M), XBI (sold out, $110.6M), AXSM (sold out, $84.6M), Verona Pharma Plc (sold out, $82.1M), PRAX (sold out, $58.6M), RXRX (sold out, $52.2M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Mar 31, 2025 on May 15, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q1 2025: RA Capital Management 13F holdings”, data as of 15 May 2025. https://funkfolio.com/gurus/peter-kolchinsky/2025-q1
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Mar 31, 2025.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Mar 31, 2025, filed May 15, 2025. Changes compare share counts with the filing for Dec 31, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $6B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 4 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.